We are live on ! Find out more
PP

PDT Partners Portfolio holdings

AUM $1.69B
1-Year Est. Return 74.01%
This Fund
S&P 500
This Quarter Est. Return
+28.35%
1 Year Est. Return
+74.01%
3 Year Est. Return
+179.69%
5 Year Est. Return
+210.81%
10 Year Est. Return
+1,321.68%
AUM
$1.48B
AUM Growth
-$34.8M
Cap. Flow
-$328M
Cap. Flow %
-22.14%
Top 10 Hldgs %
6.75%
Holding
913
New
211
Increased
150
Reduced
301
Closed
241

Top Buys

Rank Stock Value
1
SMG icon
ScottsMiracle-Gro
SMG
+$5.68M
2
ACGL icon
Arch Capital
ACGL
+$5.65M
3
DDOG icon
Datadog
DDOG
+$5.54M
4
OLLI icon
Ollie's Bargain Outlet
OLLI
+$5.38M
5
NEE icon
NextEra Energy
NEE
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 22.47%
2 Technology 21.77%
3 Consumer Discretionary 18.47%
4 Industrials 10.54%
5 Financials 8.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GYRE icon
601
Gyre Therapeutics
GYRE
$629M
$220K 0.01%
4,640
-841
-15% -$36.4K
NVMI
602
Nova
NVMI
$11.7B
$219K 0.01%
3,100
-29,000
-90% -$1.81M
VVNT
603
DELISTED
Vivint Smart Home, Inc. Class A Common Stock
VVNT
$219K 0.01%
+10,577
New +$210K
ARLO icon
604
Arlo Technologies
ARLO
$1.58B
$214K 0.01%
+27,426
New +$167K
NSTG
605
DELISTED
NanoString Technologies, Inc.
NSTG
$213K 0.01%
+3,178
New +$159K
EZPW icon
606
Ezcorp Inc
EZPW
$1.79B
$207K 0.01%
+43,252
New +$217K
VNE
607
DELISTED
Veoneer, Inc.
VNE
$206K 0.01%
9,673
-38,727
-80% -$733K
ACBI
608
DELISTED
Atlantic Capital Bancshares, Inc. Common Stock
ACBI
$206K 0.01%
+12,937
New +$189K
RAPT
609
DELISTED
RAPT Therapeutics
RAPT
$204K 0.01%
+1,289
New +$280K
MLAB icon
610
Mesa Laboratories
MLAB
$551M
$201K 0.01%
+700
New +$193K
JJSF icon
611
J&J Snack Foods
JJSF
$1.49B
$200K 0.01%
+1,288
New +$188K
ASMB icon
612
Assembly Biosciences
ASMB
$498M
$199K 0.01%
2,742
+1,865
+213% +$219K
CBIO
613
Crescent Biopharma
CBIO
$546M
$194K 0.01%
+516
New +$181K
PBI icon
614
Pitney Bowes
PBI
$2.39B
$188K 0.01%
30,514
-23,073
-43% -$139K
DTIL icon
615
Precision BioSciences
DTIL
$178M
$184K 0.01%
737
-83
-10% -$20.3K
AMRS
616
DELISTED
Amyris Inc.
AMRS
$181K 0.01%
+29,345
New +$93.8K
ARCO icon
617
Arcos Dorados Holdings
ARCO
$1.74B
$176K 0.01%
+35,428
New +$162K
XONE
618
DELISTED
The ExOne Company
XONE
$176K 0.01%
+18,495
New +$211K
MTEM
619
DELISTED
Molecular Templates, Inc.
MTEM
$175K 0.01%
1,239
-2,264
-65% -$334K
RUBY
620
DELISTED
Rubius Therapeutics, Inc
RUBY
$174K 0.01%
22,912
-26,588
-54% -$158K
YELL
621
DELISTED
Yellow Corporation Common Stock
YELL
$174K 0.01%
+39,339
New +$191K
SURF
622
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$173K 0.01%
18,754
MNRL
623
DELISTED
Brigham Minerals, Inc. Class A Common Stock
MNRL
$172K 0.01%
15,690
-5,900
-27% -$60.9K
RYZ
624
Ryerson Holding Corp
RYZ
$1.49B
$171K 0.01%
12,570
-5,546
-31% -$54.4K
OSW icon
625
OneSpaWorld
OSW
$2.64B
$167K 0.01%
16,487
-108,209
-87% -$855K

Similar funds

PDT Partners's Q4 2020 Portfolio in Review

As of Q4 2020, PDT Partners held 913 positions worth $1.48B, down 2.3% from $1.51B the previous quarter. Its ten largest holdings account for 6.7% of the portfolio.

PDT Partners withdrew a net $328M in Q4 2020, closing 241 positions and reducing 301 holdings. Its most notable exit was Lam Research, an estimated $8.46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, PDT Partners opened a new position in ScottsMiracle-Gro worth $6.59M.

  • PDT Partners's largest Q4 2020 buy was ScottsMiracle-Gro: 33,110 shares worth $6.59M.
  • PDT Partners added most to Arch Capital in Q4 2020, an estimated $5.65M increase.
  • PDT Partners's biggest Q4 2020 reduction was Ferrari, cutting an estimated $12.2M.
  • PDT Partners fully exited Lam Research in Q4 2020, selling an estimated $8.46M.
  • PDT Partners's ten largest holdings make up 6.7% of its $1.48B portfolio in Q4 2020.
  • PDT Partners opened 211 new positions and closed 241 in Q4 2020.
  • PDT Partners's portfolio value fell 2.3% quarter-over-quarter to $1.48B.

Based on PDT Partners's 13F filing for Q4 2020, filed 16 Feb 2021.